Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
1.330
+0.030 (2.31%)
At close: Apr 1, 2026, 4:00 PM EDT
1.340
+0.010 (0.75%)
After-hours: Apr 1, 2026, 7:00 PM EDT
Invivyd Revenue
In the year 2025, Invivyd had annual revenue of $53.43M with 110.47% growth. Invivyd had revenue of $17.21M in the quarter ending December 31, 2025, with 24.51% growth.
Revenue (ttm)
$53.43M
Revenue Growth
+110.47%
P/S Ratio
7.03
Revenue / Employee
$437,918
Employees
122
Market Cap
375.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 53.43M | 28.04M | 110.47% |
| Dec 31, 2024 | 25.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ginkgo Bioworks Holdings | 170.16M |
| Niagen Bioscience | 129.42M |
| Autolus Therapeutics | 75.39M |
| Enanta Pharmaceuticals | 66.98M |
| PureTech Health | 6.39M |
| Avalo Therapeutics | 59.00K |
IVVD News
- 2 days ago - Invivyd Announces Presentation at the World Vaccine Congress Washington - GlobeNewsWire
- 12 days ago - Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching - Seeking Alpha
- 27 days ago - Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 27 days ago - Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates - GlobeNewsWire
- 27 days ago - Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer - GlobeNewsWire
- 4 weeks ago - Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 - GlobeNewsWire
- 4 weeks ago - Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies - GlobeNewsWire